PharmaShots | Incisive News in 3 Shots

Subscribe Now

Regeneron

Regeneron to Present Updated Results of Linvoseltamab for Patients with Heavily Pre-treated Multiple Myeloma at ASCO 2023

Regeneron to Present Updated Results of Linvoseltamab for Patients with Heavily Pre-treated Multiple Myeloma at ASCO 2023

May 26, 2023

Regeneron and Sanofi Presented P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease at ATS and Published in the NEJM

Regeneron and Sanofi Presented P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease at A...

May 22, 2023

Insights+: The US FDA New Drug Approvals in March 2023

Insights+: The US FDA New Drug Approvals in March 2023

April 19, 2023

Regeneron’s Libtayo (cemiplimab) Receives EC’s Approval as 1L Treatment of Advanced PD-L1 Positive Non-Small Cell Lung Cancer

Regeneron’s Libtayo (cemiplimab) Receives EC’s Approval as 1L Treatment of Advanced PD-L1 Positive Non-Small Cell Lung Cancer

March 29, 2023

Regeneron and Sanofi Report P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease

Regeneron and Sanofi Report P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease

March 23, 2023

Regeneron’s Dupixent (dupilumab) Receives EC’s Approval as First Targeted Medicine for Severe Atopic Dermatitis

Regeneron’s Dupixent (dupilumab) Receives EC’s Approval as First Targeted Medicine for Severe Atopic Dermatitis

March 21, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us